Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer

PURPOSE: First-line treatment of patients with recurrent, metastatic prostate cancer involves hormone therapy with or without additional systemic therapies. Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) allows the detection of oligometastatic d...

Descripción completa

Detalles Bibliográficos
Autores principales: Stefan A. Koerber, Katharina Sprute, Clemens Kratochwil, Erik Winter, Matthias F. Haefner, Sonja Katayama, Ingmar Schlampp, Klaus Herfarth, Klaus Kopka, Ali Afshar-Oromieh, Stefanie Zschaebitz, Tim Holland-Letz, Peter L. Choyke, Dirk Jaeger, Markus Hohenfellner, Uwe Haberkorn, Juergen Debus, Frederik L. Giesel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835298/
https://www.ncbi.nlm.nih.gov/pubmed/32405735
http://dx.doi.org/10.1007/s00259-020-04777-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835298/
https://www.ncbi.nlm.nih.gov/pubmed/32405735
http://dx.doi.org/10.1007/s00259-020-04777-z

Ejemplares similares